CDER “Comprehensive” Reorganization To Follow After CBER-CDER Merger
Executive Summary
CDER plans to reorganize under indication-based divisions following the merger between the center for drugs and center for biologics, Office of New Drugs Director John Jenkins, MD, said during the Biotechnology Industry annual meeting in Washington, D.C. June 24
You may also be interested in...
US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?
FDA reaches final stages of reorganization that will better distribute an ever-increasing review workload; recent high-level departures will make filling even more management slots difficult.
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA is planning to split the Division of Neuropharmacological Drug Products into two divisions - neurology and psychiatry - as part of the upcoming reorganization of the Office of New Drugs
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA is planning to split the Division of Neuropharmacological Drug Products into two divisions - neurology and psychiatry - as part of the upcoming reorganization of the Office of New Drugs